Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_3_presentation_3_-_plaque_psoriasis [2017/04/07 22:46] makdayr |
group_3_presentation_3_-_plaque_psoriasis [2018/01/25 15:18] (current) |
||
|---|---|---|---|
| Line 3: | Line 3: | ||
| ====== Presentation 3: Plaque Psoriasis Powerpoint File ====== | ====== Presentation 3: Plaque Psoriasis Powerpoint File ====== | ||
| - | <HTML> | + | {{:psoriasis_slides.pdf|}} |
| - | + | ||
| - | <br> | + | |
| - | </HTML> | + | |
| ====== Introduction ====== | ====== Introduction ====== | ||
| Line 16: | Line 13: | ||
| {{:pi1.png|}} | {{:pi1.png|}} | ||
| - | Figure: Plaque psoriasis | + | Figure 1: Plaque psoriasis |
| Image from: http://jamanetwork.com/journals/jama/fullarticle/1104805 | Image from: http://jamanetwork.com/journals/jama/fullarticle/1104805 | ||
| </style> | </style> | ||
| Line 45: | Line 42: | ||
| {{:screen_shot_2017-04-06_at_1.18.11_pm.png|}} | {{:screen_shot_2017-04-06_at_1.18.11_pm.png|}} | ||
| - | Figure: A typical psoriatic plaque | + | Figure 2: A typical psoriatic plaque |
| Image from: http://www.wikipedia.com | Image from: http://www.wikipedia.com | ||
| {{:screen_shot_2017-04-06_at_1.23.58_pm.png|}} | {{:screen_shot_2017-04-06_at_1.23.58_pm.png|}} | ||
| - | Figure: A red and scaly scalp lesion | + | Figure 3: A red and scaly scalp lesion |
| Image from: http://nopsoriasis.net | Image from: http://nopsoriasis.net | ||
| </style> | </style> | ||
| Line 80: | Line 77: | ||
| {{:screen_shot_2017-04-06_at_1.16.39_pm.png|}} | {{:screen_shot_2017-04-06_at_1.16.39_pm.png|}} | ||
| - | Figure: Ranking the severity of psoriasis, via PASI | + | Figure 4: Ranking the severity of psoriasis, via PASI |
| Image from: http://www.healthline.com | Image from: http://www.healthline.com | ||
| </style> | </style> | ||
| Line 114: | Line 111: | ||
| {{:psor_eti_.png|}} | {{:psor_eti_.png|}} | ||
| - | Figure: The genetic linkage of plaque psoriasis | + | Figure 5: The genetic linkage of plaque psoriasis |
| Image from: https://www.slideshare.net/Gurpgork/psoriasis-35245580 | Image from: https://www.slideshare.net/Gurpgork/psoriasis-35245580 | ||
| Line 140: | Line 137: | ||
| {{:patho_psor.png|}} | {{:patho_psor.png|}} | ||
| - | Figure: Cytokine networks in psoriasis | + | Figure 6: Cytokine networks in psoriasis |
| Image from: http://www.nature.com/nature/journal/v445/n7130/abs/nature05663.html | Image from: http://www.nature.com/nature/journal/v445/n7130/abs/nature05663.html | ||
| </style> | </style> | ||
| Line 183: | Line 180: | ||
| **Systemic Agents** | **Systemic Agents** | ||
| - | SABRINA | + | Systemic agents are prescription drugs that affect the entire body. Most patients prescribed these agents will have moderate to severe psoriasis and/or psoriatic arthritis. Systemic medications are also used by those who are not responsive to or are unable to use topical medications or ultraviolet (UV) light treatment (Feldman, 2013). |
| + | |||
| + | These drugs are taken by mouth in liquid or pill form or given by injection into the skin or muscle or through intravenous (IV) infusion (Feldman, 2013). | ||
| + | |||
| + | //Methotrexate// | ||
| + | |||
| + | This drug is in a class of medications known as antimetabolites and is typically only used in moderate to severe cases of psoriasis (Feldman, 2013). Its mechanism of action involves immunosuppression, in which T-cells are deactivated in order to decrease the autoimmune response to epidermal cells (Felman, 2013). It is usually taken orally, either in pill or liquid form, but can be taken via IV (Mayo Clinic, 2015). There are risks surrounding long-term use of methotrexate, including severe liver damage or the decreased production of white and red blood cells or blood platelets (Mayo Clinic, 2015). | ||
| + | |||
| + | //Cyclosporine// | ||
| + | |||
| + | This drug is used for adults with severe psoriasis and otherwise normal immune systems. It suppresses the activity of T-cells within the immune system, which slows the growth of skin cells (Feldman, 2013). Cyclosporine is typically taken orally in 3 to 5 mg/kg per day with symptom relief within 4 weeks (Feldman, 2013). Since this drug is suppressing your immune system, this increases the patient’s chances of infection or related health problems. There are risks with taking the medication in high doses or for long-term use and these include, high blood pressure or kidney ailments (Mayo Clinic, 2015). | ||
| + | |||
| + | //Soriatane (acitretin)// | ||
| + | |||
| + | This drug is an oral retinoid, which is a synthetic form of vitamin A and usually prescribed to those with severe cases of psoriasis (Feldman, 2013). Retinoids help control the multiplication of cells, including the speed with which skin cells grow and shed, which increases in psoriasis (Mayo Clinic, 2015). The dose ranges of acitretin can be anywhere from 25 mg every other day to 50 mg daily (Feldman, 2013). Acitretin can also be prescribed in combination with UVA or PUVA therapy; shown to increase response rates (Feldman, 2013). The use of this medication may put one at risk of lip inflammation or hair loss. Those who are or may become pregnant should also be wary of this medication as it has been shown to elicit birth defects in pregnant women (Mayo Clinic, 2015). | ||
| **__MANAGEMENT__** | **__MANAGEMENT__** | ||
| Line 233: | Line 244: | ||
| Dogra, S., & Mahajan, R. (2016). Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatology Online Journal, 7(6), 471. | Dogra, S., & Mahajan, R. (2016). Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatology Online Journal, 7(6), 471. | ||
| + | |||
| + | Feldman, S. R., Pearce, D. J., Dellavalle, R. P., & Duffin, K. C. (2013). Treatment of psoriasis. UpToDate. http://www.uptodate.com (accessed April, 2017). | ||
| Fluhr, J. W., Cavallotti, C., & Berardesca, E. (2008). Emollients, moisturizers, and keratolytic agents in psoriasis. Clinics in dermatology, 26(4), 380-386. | Fluhr, J. W., Cavallotti, C., & Berardesca, E. (2008). Emollients, moisturizers, and keratolytic agents in psoriasis. Clinics in dermatology, 26(4), 380-386. | ||
| Line 275: | Line 288: | ||
| “Psoriasis Symptoms and Triggers”. WebMD. Retrieved 2017-03-29. | “Psoriasis Symptoms and Triggers”. WebMD. Retrieved 2017-03-29. | ||
| + | |||
| + | Psoriasis: Treatment and Drugs. (2015). Mayo Clinic. http://www.mayoclinic.org (accessed April, 2017). | ||
| Raychaudhuri, S. K., Maverakis, E., & Raychaudhuri, S. P. (2014). Diagnosis and classification of psoriasis. Autoimmunity reviews, 13(4), 490-495. | Raychaudhuri, S. K., Maverakis, E., & Raychaudhuri, S. P. (2014). Diagnosis and classification of psoriasis. Autoimmunity reviews, 13(4), 490-495. | ||
